FridayJun 11, 2021 11:21 am

BioMedNewsBreaks – Brain Scientific Inc.’s (BRSF) Disposable Technology Vital Amid Ongoing Pandemic

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, has developed sanitary, disposable EEG caps that are proving useful amid the ongoing pandemic. “When fighting a highly contagious disease, disposable technology is vital,” notes a recent article. This is where NeuroCap(TM) and NeuroEEG(TM), the company’s two FDA-cleared devices, can help. They offer cost-efficient, portable neurological monitoring.” The article observes that EEGs may offer a much-needed solution given that neurological conditions associated with COVID-19 are challenging to diagnose. “For example, the diagnosis of encephalopathy, one of the most frequently occurring neurological conditions in COVID-19, is mainly…

Continue Reading

ThursdayJun 10, 2021 12:42 pm

BioMedNewsBreaks – Healthy Extracts Inc.’s (HYEX) HERHEART(TM) Packs a ‘Whole Host of Health Benefits’

Healthy Extracts (OTCQB: HYEX), through its wholly owned subsidiary BergaMet NA(TM), has developed HERHEART(TM), an exclusive supplement scientifically formulated specifically for women to improve perimenopausal symptoms and cardiovascular health. The supplement’s development was influenced by the statistic that cardiovascular disease is the leading cause of death in women globally. A recent article notes, “A 2020 clinical study revealed that HERHEART reduced mood swings and hot flashes by 40% and 60%, respectively, increased energy by 45%, and improved arousal, comfort and desire by between 40% and 70%. It also reduced cholesterol levels, acted as an anti-inflammatory agent and metabolized fat. Dr.…

Continue Reading

ThursdayJun 10, 2021 12:36 pm

BioMedNewsBreaks – United Medical Equipment Business Solutions Network Inc. Expands Medication Management App with GoodRX

United Medical Equipment (“UME,” “UMEBSNI”) helps families with resources and provides a network of reliable solutions such as the Medication Management App. Available on both iOS and Android, the app is designed to provide direct and indirect patient care and education for care professionals, caregivers, students, and family members. “GoodRX is the newest addition to the app’s functions,” reads a recent article. “This feature allows users to view discount prices and coupons while managing medications all within the app. In addition, GoodRX offers same-day appointments with an online health care provider, access to at-home lab tests or tests at a…

Continue Reading

WednesdayJun 09, 2021 12:22 pm

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Aims for New Standard of Care in Visualizing Cancer

Imagin Medical’s (CSE: IME) (OTCQB: IMEXF) i/Blue Imaging System(TM) is designed to enhance tumor visualization and resection, potentially lowering recurrence rates. With a focus on establishing a new standard of care in the visualization of cancer during minimally invasive procedures, Imagin Medical is initially targeting bladder cancer, the sixth most prevalent cancer in the U.S. and the third most common in men. Imagin’s i/Blue Imaging System aims to enhance the capabilities of cystoscopies, the conventional method used to visualize bladder cancer during surgical procedures. “Combining the effectiveness of blue light cystoscopy with proprietary technology, the i/Blue Imaging System will improve…

Continue Reading

FridayJun 04, 2021 10:34 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Filling EEG Testing Gap in Pediatric Brain Diagnostics

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, was the subject of a feature piece published by Med-Tech News, a publication covering medical devices and manufacturing. The article, authored by the marketing director of BRSF, Irina Nazarova, noted that the need for EEG devices within the pediatric segment often went unmet, even though children can suffer from a number of neurological disorders, some of which could lead to more devastating outcomes if left undetected. Further, EEG testing could be used for diagnosing ADHD, a growing market need. A recent article reads, “despite the apparent…

Continue Reading

WednesdayJun 02, 2021 1:38 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Nears Dosing of Phase 2 Patients with Standout Anthracycline Therapy

CNS Pharmaceuticals (NASDAQ: CNSP) is focused on producing a treatment that improves on the effectiveness of established chemotherapy drug lomustine in increasing overall survival rates of glioblastoma multiforme (“GBM”) patients. GBM is an illness that is nearly 100% fatal in patients just over a year after diagnosis. CNS Pharmaceuticals’ lead drug candidate, Berubicin, has been granted investigational new drug (“IND”) status after promising findings. “Berubicin is a standout anthracycline therapy because of its novel apparent ability to cross the blood-brain barrier to combat neurological tumors. The drug was the subject of a Phase I trial some 15 years ago in…

Continue Reading

WednesdayJun 02, 2021 1:29 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Building Strong Commercial Pipeline for Unique PeDAL(TM) Platform

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, continues to create value for a growing customer base through its subsidiaries. Researchers from one such subsidiary, Helomics, recently completed key sequencing milestones for ovarian cancer to help build its AI-driven models of the disease. “We are building a strong commercial pipeline for our unique Patient-cEntric Discovery by Active Learning (PeDAL)(TM), which we launched at the beginning of 2021,” POAI CEO J. Melville Engle was quoted in a recent article. “PeDAL brings together the key Helomics assets of real-world longitudinal data…

Continue Reading

FridayMay 28, 2021 12:33 pm

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Eyes Potential Expansion of ‘Covid-ID Lab’

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently received the CE-IVD approval (European certification) of its 25-minute COVID-19 RT-PCR test kits (“Covid-ID Lab”). The approval facilitated initial sale and distribution of the Covid-ID Lab in Germany and, later, other parts of Europe, the Middle East and North America. The company also recently announced delivery of 2,000 units of Covid-ID Lab to an established medical distributor in Israel. This, subject to commercial regulatory approval and subsequent potential product distribution, signaled XPhyto’s entry into the Middle East. “These units will be used for clinical evaluation based on…

Continue Reading

ThursdayMay 27, 2021 11:57 am

BioMedNewsBreaks – Healthy Extracts Inc.’s (HYEX) Leading Products Backed by Research, Clinical Studies

Healthy Extracts (OTCQB: HYEX), through its two subsidiaries, BergaMet NA(TM) and Ultimate Brain Nutrients(TM) (“UBN”), is focused on the research, development and sale of natural plant-based formulations offering benefits for cardiovascular and neuro health. The targeting of these two high-growth categories reflects Healthy Extracts’ commitment to strengthening its position in the multibillion nutraceuticals market. “Research and clinical studies show positive results for two leading products of the company, BergaMet North America’s HERHEART(TM) and Ultimate Brain Nutrients’ Fuel4Thought(TM) Brain Booster. Clinical studies show positive results in brain activation, sports vision, cognitive function, clarity, energy, and ketone benefits (https://ibn.fm/WGKZN),” reads a recent…

Continue Reading

WednesdayMay 26, 2021 1:24 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Study Promising Candidate in Phase 2 GBM Trial

CNS Pharmaceuticals (NASDAQ: CNSP) is on track to begin a potentially pivotal Phase 2 trial during the second quarter of 2021. This trial of CNSP’s lead drug candidate, Berubicin, in the treatment of glioblastoma multiforme (“GBM”) is currently planned to include up to 243 subjects, randomized 2:1 (162 Berubicin/81 Lomustine) with an interim analysis when 50% of the subjects reach six months in the study. “As the first anthracycline to cross the blood-brain barrier, Berubicin was specifically designed to attack a variety of primary brain cancers and cancers metastatic to the brain,” reads a recent article on the novel candidate.…

Continue Reading

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050